Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) (MONEO)
Sponsor: Vall d'Hebron Institute of Oncology
This PHASE2 trial investigates Gastroesophageal Junction Adenocarcinoma and Stomach Neoplasms and is currently ongoing. Vall d'Hebron Institute of Oncology leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Dec 2024 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — May 2023 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Nov 2021 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2019 — Nov 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Vall d'Hebron Institute of Oncology
For direct contact, visit the study record on ClinicalTrials.gov .